ENDRA Life Sciences Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 10.06 million compared to USD 13.18 million a year ago. Basic loss per share from continuing operations was USD 1.58 compared to USD 4.56 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2905 USD | +0.28% | -10.09% | -86.30% |
05-14 | Transcript : ENDRA Life Sciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-10 | ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.30% | 3.2M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- NDRA Stock
- News ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023